The SMARTER Cardiomyopathy Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood Sample Collection.
- Who it may be relevant to
- Registry conditions: Cardiomyopathies, Hypertrophic Cardiomyopathy, Dilated Cardiomyopathy. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United Kingdom
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Genetics, Imaging and Artificial Intelligence for Precision Care in Cardiomyopathy
Overview
Cardiomyopathies are diseases of the heart muscle. Known genetic factors may account for some cardiomyopathy cases but there is still much to understand about the genetic and environmental causes and how the disease progresses. Finding new ways to diagnose and treat cardiomyopathies could improve the health and well-being of patients with these conditions. This study will collect data from individuals with cardiomyopathy or related heart muscle disease, or with a possible genetic predisposition to cardiomyopathy, and follow them over time to observe the progress of their heart and health. This study will collect DNA, blood samples, and detailed clinical \& lifestyle information at the start of the study, and data collected during routine healthcare visits over time. * learn what causes cardiomyopathy, and therefore how to treat it * understand why cardiomyopathy progresses differently in different people, to improve the ability to recognise who will benefit from different treatments at different times The investigators will collaborate with other centres internationally to collect a large of group of participants with similar cardiomyopathies, providing power to identify new pathways that cause disease and ways of predicting which participants are at risk of having more severe disease.
Interventions
- Other Blood Sample Collection
Blood for DNA and biomarker analysis
Primary outcome measures
- Incidence of genetic variants [Time frame: 5 years]
- The incidence of major adverse cardiovascular events over 5 years [Time frame: 5 years]
Eligibility criteria
Inclusion criteria
Adults with the capacity to consent Children with parental/guardian consent Male and Female
Meeting the following criteria:
- Patients with a confirmed diagnosis of cardiomyopathy or related condition
- Patients with a family member with cardiomyopathy, or a related condition
- Patients with a genetic variant that may predispose to cardiomyopathy, or a related condition
Exclusion criteria
Patients without the capacity to provide informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
United Kingdom · 2 centers
- Guys & St Thomas' NHS Foundation Trust — London
- Kings College Hospital — London
Identifiers
NCT: NCT05750147 · 22IC7783